ABIVAX Société Anonyme (ENXTPA:ABVX) Draws UEG Week Focus As Obefazimod Valuation Debate Builds

ABIVAX Société Anonyme (ENXTPA:ABVX) has drawn fresh attention after announcing that seven scientific abstracts on its lead drug candidate obefazimod will be featured at United European Gastroenterology Week 2026 in Barcelona.

Against that backdrop, ABIVAX Société Anonyme’s recent UEG Week spotlight lands after a tough run for the share price, which has fallen 31.3% year to date and 34.2% over 90 days, even though the three year total shareholder return remains very large.

Scan other high-conviction biopharma ideas moving on clinical catalysts with the curated 127 healthcare AI stocks, which can sit alongside ABIVAX Société Anonyme on your watchlist.

For ABIVAX Société Anonyme, a sharp three year gain now sits alongside a deep recent pullback. Is most of obefazimod’s potential already reflected in the share price, or does the current valuation still leave meaningful upside from here?

Most Popular Narrative: 64% Undervalued

ABIVAX Société Anonyme last closed at €79, while the most followed valuation story on the stock points to a fair value of €220. This presents a very wide gap for investors to consider.

In my opinion, Abivax is worth much more than its current share price of around €136. The market still seems to value the company as if there is a lot of uncertainty, but I believe much of that uncertainty has now been reduced. The company's lead drug, obefazimod, has delivered strong Phase 3 results in ulcerative colitis, and recent safety updates have helped rebuild investor confidence. At the same time, Abivax has raised enough cash to fund its operations for several years, meaning it can focus on getting the drug approved and launched instead of worrying about raising more money.

See why 7 investors see ABIVAX Société Anonyme as 64% undervalued.

Result: Fair Value of €220 (UNDERVALUED)

Still, the ABIVAX Société Anonyme story can break if regulators push back on obefazimod approvals or if future trial readouts fail to match expectations.

Find out about the key risks to this ABIVAX Société Anonyme narrative.

Another View: SWS DCF Model Points Higher Risk

A different lens on ABIVAX Société Anonyme comes from the SWS DCF model, which estimates future cash flow value at €71.2 per share. With the stock at €79, that framework suggests the shares are overvalued rather than discounted. Which yardstick should drive your own expectations from here?

To understand how this cash flow based view is built and what assumptions sit under it, take a closer look at the Look into how the SWS DCF model arrives at its fair value..

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out ABIVAX Société Anonyme for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 178 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals around ABIVAX Société Anonyme can create plenty of noise. Move fast, review the underlying data, and weigh both sides through the 1 key reward and 1 important warning sign.

Looking for more ABIVAX Société Anonyme sized ideas?

Do not stop with one ticker. Use the Simply Wall St screener to line up fresh opportunities while this research is still front of mind.

• Target dependable cash generators by scanning a list of solid balance sheet and fundamentals (204 results) that can sit alongside ABIVAX Société Anonyme as potential core holdings.
• Hunt for mispriced quality by reviewing a curated 178 high quality undervalued stocks that could complement a higher risk biotech exposure.
• Build resilience into your income stream by checking a focused 223 dividend fortresses that may balance out more volatile growth ideas.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com